- Home
- ONL vs EDIT Comparison
ONL vs EDIT Comparison
Compare ONL & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONL
- EDIT
- Stock Information
- Founded
- ONL 2021
- EDIT 2013
- Country
- ONL United States
- EDIT United States
- Employees
- ONL N/A
- EDIT N/A
- Industry
- ONL Real Estate Investment Trusts
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ONL Real Estate
- EDIT Health Care
- Exchange
- ONL Nasdaq
- EDIT Nasdaq
- Market Cap
- ONL 111.3M
- EDIT 115.5M
- IPO Year
- ONL N/A
- EDIT 2016
- Fundamental
- Price
- ONL $1.93
- EDIT $1.77
- Analyst Decision
- ONL Hold
- EDIT Buy
- Analyst Count
- ONL 1
- EDIT 13
- Target Price
- ONL N/A
- EDIT $6.73
- AVG Volume (30 Days)
- ONL 636.5K
- EDIT 1.8M
- Earning Date
- ONL 05-07-2025
- EDIT 05-12-2025
- Dividend Yield
- ONL 4.12%
- EDIT N/A
- EPS Growth
- ONL N/A
- EDIT N/A
- EPS
- ONL N/A
- EDIT N/A
- Revenue
- ONL $154,796,000.00
- EDIT $35,837,000.00
- Revenue This Year
- ONL N/A
- EDIT N/A
- Revenue Next Year
- ONL N/A
- EDIT N/A
- P/E Ratio
- ONL N/A
- EDIT N/A
- Revenue Growth
- ONL N/A
- EDIT N/A
- 52 Week Low
- ONL $1.46
- EDIT $0.91
- 52 Week High
- ONL $4.39
- EDIT $6.22
- Technical
- Relative Strength Index (RSI)
- ONL 52.17
- EDIT 58.86
- Support Level
- ONL $1.63
- EDIT $1.70
- Resistance Level
- ONL $1.97
- EDIT $1.95
- Average True Range (ATR)
- ONL 0.11
- EDIT 0.16
- MACD
- ONL 0.01
- EDIT 0.03
- Stochastic Oscillator
- ONL 54.77
- EDIT 70.25
About ONL Orion Office REIT Inc.
Orion Properties Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased on a single-tenant net lease basis to creditworthy clients. The portfolio of the company includes traditional office buildings, governmental offices, medical offices, laboratories, and others. The Company operates in one business segment: direct ownership and operation of commercial real estate.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.